HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
- PMID: 8599114
- DOI: 10.1126/science.271.5255.1582
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time
Abstract
A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t 1/2 = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days (t 1/2 = 0.24 days). The estimated average total HIV-1 production was 10.3 x 10(9) virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time--defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles--is 2.6 days. These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.
Similar articles
-
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.Nature. 1995 Jan 12;373(6510):123-6. doi: 10.1038/373123a0. Nature. 1995. PMID: 7816094
-
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.N Engl J Med. 1995 Dec 7;333(23):1534-9. doi: 10.1056/NEJM199512073332204. N Engl J Med. 1995. PMID: 7477168 Clinical Trial.
-
Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.J Infect Dis. 1996 Feb;173(2):321-9. doi: 10.1093/infdis/173.2.321. J Infect Dis. 1996. PMID: 8568292 Clinical Trial.
-
HIV-1 dynamics in vivo: implications for therapy.Nat Rev Microbiol. 2003 Dec;1(3):181-90. doi: 10.1038/nrmicro772. Nat Rev Microbiol. 2003. PMID: 15035022 Review.
-
Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.HIV Clin Trials. 2008 Nov-Dec;9(6):418-27. doi: 10.1310/hct0906-418. HIV Clin Trials. 2008. PMID: 19203907 Review.
Cited by
-
Apollo: A comprehensive GPU-powered within-host simulator for viral evolution and infection dynamics across population, tissue, and cell.bioRxiv [Preprint]. 2024 Oct 12:2024.10.07.617101. doi: 10.1101/2024.10.07.617101. bioRxiv. 2024. PMID: 39416208 Free PMC article. Preprint.
-
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs.Viruses. 2024 Sep 18;16(9):1484. doi: 10.3390/v16091484. Viruses. 2024. PMID: 39339960 Free PMC article. Review.
-
HIV-1 diversity in viral reservoirs obtained from circulating T-cell subsets during early ART and beyond.PLoS Pathog. 2024 Sep 18;20(9):e1012526. doi: 10.1371/journal.ppat.1012526. eCollection 2024 Sep. PLoS Pathog. 2024. PMID: 39292732 Free PMC article.
-
Identification of antibody targets associated with lower HIV viral load and viremic control.PLoS One. 2024 Sep 17;19(9):e0305976. doi: 10.1371/journal.pone.0305976. eCollection 2024. PLoS One. 2024. PMID: 39288118 Free PMC article. Clinical Trial.
-
Applying quantitative and systems pharmacology to drug development and beyond: An introduction to clinical pharmacologists.Indian J Pharmacol. 2024 Jul 1;56(4):268-276. doi: 10.4103/ijp.ijp_644_23. Epub 2024 Sep 10. Indian J Pharmacol. 2024. PMID: 39250624 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical